BioCentury | Sep 25, 2020
Product Development
Novo makes obesity pick as amylin/GLP-1 combo promises gastric bypass-like efficacy
...five obesity programs, Novo pins hopes on amylin/GLP-1...
...for obesity with the pick of an amylin/semaglutide...
...combinations with other therapies, in particular the amylin...
...for obesity with the pick of an amylin/semaglutide...
...combinations with other therapies, in particular the amylin...